Your session is about to expire
← Back to Search
Cryptosporidium parvum oocysts (ABO809) for Cryptosporidiosis
Study Summary
This trial will test if a specific kind of Cryptosporidium causes diarrhea in humans, by giving it to them and seeing if they get sick.
- Cryptosporidiosis
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Are there any available vacancies in this clinical trial?
"As per the information currently available on clinicaltrials.gov, this medical study is not accepting participants at present. The trial was initially posted in April of 2022 and last updated November 4th 2022; however, there are presently 772 other studies that have open enrollment policies."
Does the study have an age restriction and, if so, who can qualify?
"Patients who are of legal age and younger than 50 years old can take part in this medical trial."
What are the criteria for participation in this research endeavor?
"To meet the criteria of this trial, potential participants must suffer from cryptosporidiosis and be between 18 to 50 years old. Upwards of 30 individuals will have the opportunity to join this experiment."
Has the ABO809 strain of Cryptosporidium parvum oocysts been sanctioned by the FDA?
"As this is a Phase 1 trial, with scarce evidence to support its safety or efficacy, Cryptosporidium parvum oocysts (ABO809) was assigned an initial score of one."
Share this study with friends
Copy Link
Messenger